GSK's Arexvy vaccine under EMA review for adult use

GSK's RSV vaccine, Arexvy, is under review by the EMA for use in adults aged 18 and over, with a regulatory decision expected in the first half of 2026; this expands the potential market for Arexvy, which is already approved for older adults and at-risk individuals aged 50-59, and represents a significant step in broadening the vaccine’s reach to a wider adult population.

Analysis

GSK plc has achieved a notable regulatory advancement as the European Medicines Agency (EMA) has commenced the review process for its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, for use in adults aged 18 and over. This development, which has generated a strongly positive sentiment (overall score 0.75, GSK-specific 0.8), represents a significant potential expansion of Arexvy's addressable market beyond its current approvals for adults aged 60 and older and at-risk individuals aged 50-59. A regulatory decision is anticipated in the first half of 2026. Given that RSV is a widespread virus capable of causing severe respiratory illness, hospitalizations, and fatalities, particularly in vulnerable groups, broadening Arexvy's availability to a wider adult population could drive substantial future revenue. Arexvy, which combines a recombinant RSV glycoprotein F with GSK’s proprietary AS01E adjuvant, was the first RSV vaccine approved in the European Economic Area for older adults and is currently approved in over 60 countries for individuals 60 years of age and older, and in over 50 markets for adults aged 50-59 with certain medical conditions. GSK is also pursuing expanded indications in other key regions, including the United States and Japan, underscoring its strategy to maximize the vaccine's market penetration.

Key Decisions for Investors

• Investors should recognize this EMA review initiation as a positive long-term catalyst for GSK, contingent upon successful approval for the expanded adult population anticipated in the first half of 2026.
• It is advisable to monitor ongoing regulatory milestones concerning Arexvy's review process in Europe, as well as market expansion efforts and regulatory progress in other significant regions such as the United States and Japan.
• Consider the 2026 timeline for potential revenue contributions from this broader indication and assess GSK's competitive positioning within the evolving RSV vaccine landscape as this date approaches.